Filing Details
- Accession Number:
- 0001818382-22-000159
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-09-19 16:33:02
- Reporting Period:
- 2022-09-15
- Accepted Time:
- 2022-09-19 16:33:02
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1818382 | Humacyte Inc. | HUMA | Biological Products, (No Disgnostic Substances) (2836) | 851763759 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1878024 | Ayabudge Llc | 2525 East North Carolina Highway 54 Durham NC 27713 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-09-15 | 1,522,500 | $4.00 | 18,930,004 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The sale was made by the Reporting Person in a block trade. The purchaser is an existing investor of the Issuer, who had previously participated in the Issuer's PIPE financing transaction, and was interested in increasing its ownership of the Humacyte, Inc. The transaction enabled Mr. Brady Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for the purchaser to acquire a large block of shares at a time that Humacyte, Inc. was not conducting a financing and was not making any additional shares available for purchase. Mr. Dougan, directly and indirectly, remains the largest shareholder of the Issuer.